UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
September 27, 2004
CONNETICS CORPORATION
| Delaware | 0-27406 | 94-3173928 | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
3290 West Bayshore Road, Palo Alto, California 94303
(650) 843-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||
| Item 8.01 Other Events. | ||||||||
| Item 9.01 Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 8.01 Other Events.
On September 27, 2004, Connetics Corporation announced that it commenced the Phase III clinical program for Desilux™, a low-potency topical steroid, formulated with 0.05% desonide in the Company’s proprietary emollient foam delivery vehicle. The clinical program will focus on atopic dermatitis and is designed to include infants from three months of age and children up to 17 years of age.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release dated September 27, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CONNETICS CORPORATION | ||||
| By: | /s/ Katrina J. Church | |||
| Katrina J. Church Executive Vice President, General Counsel and Secretary | ||||
Date: September 28, 2004
